###begin article-title 0
Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB
###end article-title 0
###begin p 1
###xml 566 574 <span type="species:ncbi:9606">patients</span>
Members of the vascular endothelial growth factor (VEGF) family are key signaling proteins in the induction and regulation of angiogenesis, both during development and in pathological conditions. However, signaling mediated through VEGF family proteins and their receptors has recently been shown to have direct effects on neurons and glial cells. In the present study, we immunocytochemically investigated the expression and cellular distribution of VEGFA, VEGFB, and their associated receptors (VEGFR-1 and VEGFR-2) in focal cortical dysplasia (FCD) type IIB from patients with medically intractable epilepsy. Histologically normal temporal cortex and perilesional regions displayed neuronal immunoreactivity (IR) for VEGFA, VEGFB, and VEGF receptors (VEGFR-1 and VEGFR-2), mainly in pyramidal neurons. Weak IR was observed in blood vessels and there was no notable glial IR within the grey and white matter. In all FCD specimens, VEGFA, VEGFB, and both VEGF receptors were highly expressed in dysplastic neurons. IR in astroglial and balloon cells was observed for VEGFA and its receptors. VEGFR-1 displayed strong endothelial staining in FCD. Double-labeling also showed expression of VEGFA, VEGFB and VEGFR-1 in cells of the microglia/macrophage lineage. The neuronal expression of both VEGFA and VEGFB, together with their specific receptors in FCD, suggests autocrine/paracrine effects on dysplastic neurons. These autocrine/paracrine effects could play a role in the development of FCD, preventing the death of abnormal neuronal cells. In addition, the expression of VEGFA and its receptors in glial cells within the dysplastic cortex indicates that VEGF-mediated signaling could contribute to astroglial activation and associated inflammatory reactions.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">58</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR81">81</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
The vascular endothelial growth factor (VEGF) family includes seven members which are structurally homologous, but display molecular and functional diversity [58, 81]. VEGFA, the most well known member of the VEGF family, is a crucial regulator of angiogenesis and vascular permeability in both physiological and pathological conditions such as tumor growth, chronic inflammation, and ischemia [10, 16, 19]. In addition to the unquestioned role in angiogenesis, it has recently been shown that VEGFA has direct trophic effects on neuronal and glial cells in the central nervous system [10, 22, 25, 53].
###end p 4
###begin p 5
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR81">81</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">63</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">68</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">69</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR70">70</xref>
VEGFB is most closely related to VEGFA [46, 81]; however, the biological function of VEGFB is less well characterized than the function of VEGFA. VEGFB is expressed early during development and appears to have prominent expression in the central nervous system [1, 36]. Additionally, VEGFB has been shown to function as an angiogenic and neuroprotective protein [29, 63, 68] and recent evidence suggests a role for VEGFB in neurogenesis [69, 70].
###end p 5
###begin p 6
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR81">81</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR81">81</xref>
The diverse functions of VEGF proteins can be explained by their differential binding to signaling VEGF receptors [VEGFRs; VEGFR-1 (Flt-1), VEGFR-2 (Flk1/KDR), and VEGFR-3 (Flt-4) [50, 81]]. VEGFA binds to VEGFR-1 and VEGFR-2, whereas VEGFB binds specifically to VEGFR-1 and not to VEGFR-2 [81].
###end p 6
###begin p 7
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGFB</italic>
###xml 948 950 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 302 306 <span type="species:ncbi:10116">rats</span>
###xml 508 513 <span type="species:ncbi:9606">human</span>
###xml 656 661 <span type="species:ncbi:9606">human</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
###xml 912 917 <span type="species:ncbi:9606">human</span>
###xml 1030 1035 <span type="species:ncbi:9606">human</span>
The VEGF-signaling pathway, involving both neuronal and glial cells, has been implicated in several neurological disorders, including neurodegeneration, stroke, and cerebral and spinal trauma [10]. In addition, expression of VEGFA is upregulated in neuronal and glial cells after epileptic seizures in rats [13], suggesting a role for VEGFA in seizure disorders. A recent study points to a neuroprotective role for VEGFA following status epilepticus [45]. The relevance of these findings in animal models to human epileptic disorders is uncertain. Using serial analysis of gene expression (SAGE), we recently identified the VEGFB gene to be upregulated in human tissue from a patient with focal cortical dysplasia (FCD) and intractable epilepsy compared to control cortex (Boer et al., unpublished observations). Upregulation of VEGFA and its receptor has also been recently shown in the hippocampus of cases of human temporal lobe epilepsy (TLE) [56]. However, the distribution of VEGFA, VEGFB, and VEGFRs in epilepsy-associated human malformations of cortical development has not yet been defined.
###end p 7
###begin p 8
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR73">73</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
In the present study, we investigated the expression of both VEGFA and VEGFB and their receptors (VEGFR-1 and VEGFR-2) in patients with FCD, which is a developmental disorder known to be a major cause of intractable epilepsy [73]. We report the specific cellular distribution, including both the neuronal and the glial components of the dysplastic cortex, and we discuss the potential role of VEGFA, VEGFB, and their receptors in the histogenesis and epileptogenesis of this developmental lesion.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Subjects
###end title 10
###begin p 11
###xml 280 288 <span type="species:ncbi:9606">patients</span>
The cases included in this study were obtained from the databases of the Departments of Neuropathology of the Academic Medical Center (University of Amsterdam; UVA) in Amsterdam and the University Medical Center in Utrecht (UMCU). We examined surgically resected tissue from nine patients undergoing epilepsy surgery for focal cortical dysplasia. Informed consent was obtained for the use of brain tissue and for access to medical records for research purposes. The tissue was obtained and used in a manner compliant with the Declaration of Helsinki.
###end p 11
###begin p 12
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR74">74</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 994 1001 994 1001 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1001 1071 1001 1071 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13">Summary of clinical findings of patients with focal cortical dysplasia</p>
###xml 1001 1071 1001 1071 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="13">Summary of clinical findings of patients with focal cortical dysplasia</p></caption>
###xml 1071 1094 1071 1094 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient/sex/age (years)</th>
###xml 1094 1103 1094 1103 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diagnosis</th>
###xml 1103 1131 1103 1131 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Duration of epilepsy (years)</th>
###xml 1131 1143 1131 1143 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Seizure type</th>
###xml 1143 1154 1143 1154 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Engel class</th>
###xml 1071 1154 1071 1154 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Patient/sex/age (years)</th><th align="left">Diagnosis</th><th align="left">Duration of epilepsy (years)</th><th align="left">Seizure type</th><th align="left">Engel class</th></tr>
###xml 1071 1154 1071 1154 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Patient/sex/age (years)</th><th align="left">Diagnosis</th><th align="left">Duration of epilepsy (years)</th><th align="left">Seizure type</th><th align="left">Engel class</th></tr></thead>
###xml 1154 1160 1154 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1/M/11</td>
###xml 1160 1167 1160 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1167 1169 1167 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1169 1172 1169 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1172 1173 1172 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1154 1173 1154 1173 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1/M/11</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1173 1179 1173 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2/M/31</td>
###xml 1179 1186 1179 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1186 1188 1186 1188 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1188 1191 1188 1191 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1191 1192 1191 1192 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1173 1192 1173 1192 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2/M/31</td><td align="left">FCD IIB</td><td char="." align="char">20</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1192 1198 1192 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3/F/25</td>
###xml 1198 1205 1198 1205 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1205 1206 1205 1206 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1206 1209 1206 1209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1209 1210 1209 1210 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1192 1210 1192 1210 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3/F/25</td><td align="left">FCD IIB</td><td char="." align="char">9</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1210 1216 1210 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4/F/22</td>
###xml 1216 1223 1216 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1223 1225 1223 1225 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1225 1232 1225 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS/SGS</td>
###xml 1232 1233 1232 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1210 1233 1210 1233 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4/F/22</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS/SGS</td><td align="left">I</td></tr>
###xml 1233 1239 1233 1239 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/M/18</td>
###xml 1239 1246 1239 1246 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1246 1248 1246 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14</td>
###xml 1248 1251 1248 1251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1251 1252 1251 1252 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1233 1252 1233 1252 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5/M/18</td><td align="left">FCD IIB</td><td char="." align="char">14</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1252 1258 1252 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6/M/17</td>
###xml 1258 1265 1258 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1265 1267 1265 1267 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1267 1270 1267 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1270 1271 1270 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1252 1271 1252 1271 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6/M/17</td><td align="left">FCD IIB</td><td char="." align="char">10</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1271 1277 1271 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7/F/16</td>
###xml 1277 1284 1277 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1284 1286 1284 1286 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1286 1289 1286 1289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1289 1290 1289 1290 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1271 1290 1271 1290 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">7/F/16</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1290 1296 1290 1296 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8/M/29</td>
###xml 1296 1303 1296 1303 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1303 1305 1303 1305 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1305 1308 1305 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1308 1309 1308 1309 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1290 1309 1290 1309 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">8/M/29</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1309 1315 1309 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9/M/28</td>
###xml 1315 1322 1315 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FCD IIB</td>
###xml 1322 1324 1322 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1324 1327 1324 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CPS</td>
###xml 1327 1328 1327 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1309 1328 1309 1328 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">9/M/28</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr>
###xml 1154 1328 1154 1328 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">1/M/11</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">2/M/31</td><td align="left">FCD IIB</td><td char="." align="char">20</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">3/F/25</td><td align="left">FCD IIB</td><td char="." align="char">9</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">4/F/22</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS/SGS</td><td align="left">I</td></tr><tr><td align="left">5/M/18</td><td align="left">FCD IIB</td><td char="." align="char">14</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">6/M/17</td><td align="left">FCD IIB</td><td char="." align="char">10</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">7/F/16</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">8/M/29</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">9/M/28</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr></tbody>
###xml 1071 1328 1071 1328 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Patient/sex/age (years)</th><th align="left">Diagnosis</th><th align="left">Duration of epilepsy (years)</th><th align="left">Seizure type</th><th align="left">Engel class</th></tr></thead><tbody><tr><td align="left">1/M/11</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">2/M/31</td><td align="left">FCD IIB</td><td char="." align="char">20</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">3/F/25</td><td align="left">FCD IIB</td><td char="." align="char">9</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">4/F/22</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS/SGS</td><td align="left">I</td></tr><tr><td align="left">5/M/18</td><td align="left">FCD IIB</td><td char="." align="char">14</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">6/M/17</td><td align="left">FCD IIB</td><td char="." align="char">10</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">7/F/16</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">8/M/29</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">9/M/28</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr></tbody></table>
###xml 1328 1331 1328 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCD</italic>
###xml 1358 1361 1358 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CPS</italic>
###xml 1388 1391 1388 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SGS</italic>
###xml 1328 1422 1328 1422 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="14"><italic>FCD</italic> focal cortical dysplasia, <italic>CPS</italic> complex partial seizures, <italic>SGS</italic> secondary generalized seizures</p>
###xml 1328 1422 1328 1422 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="14"><italic>FCD</italic> focal cortical dysplasia, <italic>CPS</italic> complex partial seizures, <italic>SGS</italic> secondary generalized seizures</p></table-wrap-foot>
###xml 994 1422 994 1422 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="13">Summary of clinical findings of patients with focal cortical dysplasia</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient/sex/age (years)</th><th align="left">Diagnosis</th><th align="left">Duration of epilepsy (years)</th><th align="left">Seizure type</th><th align="left">Engel class</th></tr></thead><tbody><tr><td align="left">1/M/11</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">2/M/31</td><td align="left">FCD IIB</td><td char="." align="char">20</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">3/F/25</td><td align="left">FCD IIB</td><td char="." align="char">9</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">4/F/22</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS/SGS</td><td align="left">I</td></tr><tr><td align="left">5/M/18</td><td align="left">FCD IIB</td><td char="." align="char">14</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">6/M/17</td><td align="left">FCD IIB</td><td char="." align="char">10</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">7/F/16</td><td align="left">FCD IIB</td><td char="." align="char">11</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">8/M/29</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr><tr><td align="left">9/M/28</td><td align="left">FCD IIB</td><td char="." align="char">21</td><td align="left">CPS</td><td align="left">I</td></tr></tbody></table><table-wrap-foot><p textid="14"><italic>FCD</italic> focal cortical dysplasia, <italic>CPS</italic> complex partial seizures, <italic>SGS</italic> secondary generalized seizures</p></table-wrap-foot></table-wrap>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 223 230 <span type="species:ncbi:9606">patient</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
The classification system proposed by Palmini et al. [48] was used for grading the degree of FCD and only patients with FCD type IIB located in the temporal lobe were included. The clinical characteristics derived from the patient's medical records are summarized in Table 1. The predominant type of seizure pattern was that of complex partial seizures, which were resistant to maximal doses of antiepileptic drugs (AEDs; carbamazepine, valproic acid, phenytoin, levetiracetam, oxcarbazepine, and clonazepam). Information concerning the exact time of last seizure occurrence prior to surgical resection was not available. However, all the patients included in our series did not have seizure activity in the last 24 h before surgery. The patients underwent presurgical evaluation [74]. Intraoperative ECoG was performed routinely in all operations for tailoring of surgery and we classified the post-operative seizure outcome according to Engel [17]. Follow-up period ranged from 1 to 9 years. Table 1Summary of clinical findings of patients with focal cortical dysplasiaPatient/sex/age (years)DiagnosisDuration of epilepsy (years)Seizure typeEngel class1/M/11FCD IIB11CPSI2/M/31FCD IIB20CPSI3/F/25FCD IIB9CPSI4/F/22FCD IIB21CPS/SGSI5/M/18FCD IIB14CPSI6/M/17FCD IIB10CPSI7/F/16FCD IIB11CPSI8/M/29FCD IIB21CPSI9/M/28FCD IIB21CPSIFCD focal cortical dysplasia, CPS complex partial seizures, SGS secondary generalized seizures
###end p 12
###begin p 13
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Summary of clinical findings of patients with focal cortical dysplasia
###end p 13
###begin p 14
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCD</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CPS</italic>
###xml 60 63 60 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SGS</italic>
FCD focal cortical dysplasia, CPS complex partial seizures, SGS secondary generalized seizures
###end p 14
###begin p 15
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Normal-appearing control cortex/white matter from temporal region was obtained at autopsy from five adult control patients (male/female: 2/3; mean age 42, range 17-55) without history of neurological diseases. All autopsies were performed within 12 h after death (post mortem delay: 11, 11.5, 9, 8.5, 6). The cause of death was represented by acute myocardial infarction. In addition, four of the nine FCD cases contained sufficient amount of perilesional zone (normal-appearing cortex/white matter adjacent to the lesion), for comparison with the autopsy specimens. This material represents good disease control tissue, since it is exposed to the same seizure activity, drugs, fixation time, and the age and gender are also the same.
###end p 15
###begin title 16
Tissue preparation
###end title 16
###begin p 17
Tissue was fixed in 10% buffered formalin and embedded in paraffin. Two representative paraffin blocks per case (containing the complete lesion or the largest part of the lesion resected at surgery) were sectioned, stained, and assessed. Paraffin-embedded tissue was sectioned at 6 mum, mounted on organosilane-coated slides (Sigma, St Louis, MO) and used for histological and immunocytochemical reactions as described below. Frozen tissue from control cortex and FCD tissue, stored at -80degreesC, was used for western blot analysis.
###end p 17
###begin title 18
Antibody characterization
###end title 18
###begin p 19
###xml 149 155 <span type="species:ncbi:9986">rabbit</span>
###xml 202 207 <span type="species:ncbi:10090">mouse</span>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 281 287 <span type="species:ncbi:9986">rabbit</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
###xml 555 560 <span type="species:ncbi:10090">mouse</span>
###xml 582 587 <span type="species:ncbi:10090">mouse</span>
###xml 624 629 <span type="species:ncbi:10090">mouse</span>
To document the presence of a heterogeneous population of cells, we used the following antibodies: glial fibrillary acidic protein (GFAP; polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4,000; monoclonal mouse, DAKO; 1:50), vimentin (mouse clone V9, DAKO; 1:1,000), MAP2 (polyclonal rabbit; Chemicon; 1:500), neuronal nuclear protein (NeuN; mouse clone MAB377, Chemicon, Temecula, CA, USA; 1:2,000), non-phosphorylated neurofilament (SMI311; Sternberger monoclonals, Lutherville, MD; 1:1,000), human leukocyte antigen (HLA)-DP, -DQ, -DR (CR3/43; monoclonal mouse, DAKO; 1:400), CD68 (mouse clone PG-M1, DAKO; 1:200) and CD31 (mouse clone JC70A, DAKO; 1:100).
###end p 19
###begin p 20
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 677 678 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">64</xref>
###xml 1183 1185 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR80">80</xref>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
###xml 229 235 <span type="species:ncbi:9986">rabbit</span>
###xml 380 386 <span type="species:ncbi:9986">rabbit</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 501 507 <span type="species:ncbi:9986">rabbit</span>
###xml 575 580 <span type="species:ncbi:10090">mouse</span>
###xml 878 883 <span type="species:ncbi:9606">human</span>
###xml 984 989 <span type="species:ncbi:9606">human</span>
###xml 1160 1165 <span type="species:ncbi:9606">human</span>
For the detection of VEGFA, VEGFB, and their receptors, the following antibodies (Abs) were used: VEGFA (G153-694, monoclonal mouse; recognizing VEGF 165 and 189 [51], Pharmingen, CA, USA; 1:100), VEGFA (A-20, SC-152, polyclonal rabbit; raised against the N-terminus of VEGFA, recognizing VEGF 121, 165 and 189, Santa Cruz Bio., CA, USA; 1:100), VEGFB (H-70, SC-13083, polyclonal rabbit; raised against amino acids 1-70 of human VEGFB, Santa Cruz Bio.; 1:20), Flt-1 (VEGFR-1; C-17, SC-316, polyclonal rabbit, Santa Cruz Bio.; 1:100), Flk-1 (VEGFR-2; A-3, SC-6251, monoclonal mouse; Santa Cruz Bio.; 1:100). To allow comparative analysis, we used on frozen specimens of normal (n = 3) and FCD tissue (n = 2), two additional antibodies (which are not suitable for staining paraffin-embedded, formalin-fixed tissue): VEGFR-1 (clone Flt-19, 1:400; developed against the recombinant human extracellular domain of VEGFR-1) and VEGFR-2 (clone KDR-1, 1:400; developed against the recombinant human extracellular domain of VEGFR-2), kindly provided by Dr. H. A. Weich (National Research Center for Biotechnology, Braunschweig, Germany), and previously characterized on human tissues [49, 64, 80]. Similar immunoreactivity patterns were observed on paraffin-embedded and frozen tissue.
###end p 20
###begin p 21
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 807 813 807 813 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 813 1019 813 1016 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22">Representative immunoblot of VEGFA, VEGFB, VEGFR-1, and VEGFR-2 in total homogenates from control cortex and FCD tissue. Expression of &#946;-actin (as reference protein) is shown in the same protein extracts</p>
###xml 813 1019 813 1016 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22">Representative immunoblot of VEGFA, VEGFB, VEGFR-1, and VEGFR-2 in total homogenates from control cortex and FCD tissue. Expression of &#946;-actin (as reference protein) is shown in the same protein extracts</p></caption>
###xml 1019 1019 1016 1016 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig1_HTML" id="MO1"/>
###xml 807 1019 807 1016 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="22">Representative immunoblot of VEGFA, VEGFB, VEGFR-1, and VEGFR-2 in total homogenates from control cortex and FCD tissue. Expression of &#946;-actin (as reference protein) is shown in the same protein extracts</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig1_HTML" id="MO1"/></fig>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 662 667 <span type="species:ncbi:9606">human</span>
The specificity of the antibodies used for immunocytochemistry on paraffin-embedded, formalin-fixed tissue (VEGFA, VEGFB, VEGFR-1, VEGFR-2; Santa Cruz Bio.), was further tested by performing western blot analysis of total homogenates of human control cortex. We also include one FCD case of which sufficient frozen material for blot analysis was available (Fig. 1). VEGFR1 and VEGFR-2 receptor proteins were detectable as a band of approximately 180 and 200 kDa, respectively; VEGFB was detectable as a band of approximately 40 kDa; VEGFA labeled a prominent band at approximately 48 kDa and a light band at 21 kDa (reducing conditions), as recently reported in human brain tissue (control hippocampus and FCD; [56]). All immunoreactive bands disappeared after preadsorption with the corresponding peptide. Fig. 1Representative immunoblot of VEGFA, VEGFB, VEGFR-1, and VEGFR-2 in total homogenates from control cortex and FCD tissue. Expression of beta-actin (as reference protein) is shown in the same protein extracts
###end p 21
###begin p 22
Representative immunoblot of VEGFA, VEGFB, VEGFR-1, and VEGFR-2 in total homogenates from control cortex and FCD tissue. Expression of beta-actin (as reference protein) is shown in the same protein extracts
###end p 22
###begin p 23
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">65</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 1128 1132 <span type="species:ncbi:9925">goat</span>
###xml 1138 1144 <span type="species:ncbi:9986">rabbit</span>
###xml 1156 1167 <span type="species:ncbi:3704">horseradish</span>
###xml 1377 1382 <span type="species:ncbi:10090">mouse</span>
For immunoblot analysis, human normal cortex (n = 3) and FCD (n = 1) samples were homogenized in lysis buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1% NP-40, Na-orthevanadate (10.4 mg/ml), 5 mM EDTA (pH 8.0), 5 mM NaF, and protease inhibitor cocktail (Boehringer Mannheim, Germany). Protein content was determined using the bicinchoninic acid method [65]. Non-reducing conditions were used to improve the detection of the VEGFA antibody, as previously reported [8]. For electrophoresis, equal amounts of proteins (30 mug/lane) were separated by sodium dodecylsulfate-polyacrylamide gel electrophoretic (SDS-PAGE) analysis in 7.5-12.5% gels. Separated proteins were transferred to nitrocellulose paper for 1 h and 30 min, using a semi-dry electroblotting system (BioRad, Transblot SD, Hercules, CA, USA). Blots were incubated overnight in TTBS (20 mM Tris , 150 mM NaCl, 0.1% Tween, pH 7.5)/5% non-fat dry milk, containing the primary antibody (VEGFA, VEGFR-1, and VEGFR-2, 1:1,000; VEGFB, 1:200). After several washes in TTBS, the membranes were incubated in TTBS/5% non-fat dry milk/1% BSA, containing the goat anti-rabbit coupled to horseradish peroxidase (1:2,500; Dako, Denmark) for 1 h. After washes in TTBS, immunoreactivity was visualized using an enhanced chemiluminescence kit (Amersham, Buckinghamshire, UK). Expression of beta-actin (monoclonal mouse, Sigma, St Louis, MO; 1:50,000) was used as reference protein. Because of the limited availability of frozen material from FCD cases, a complete analysis with statistical comparison between control and FCD by immunoblot could not be performed.
###end p 23
###begin title 24
Immunocytochemistry
###end title 24
###begin p 25
###xml 77 78 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 353 357 <span type="species:ncbi:9925">goat</span>
Sections were deparaffinized, re-hydrated, and incubated for 20 min in 0.3% H2O2 diluted in methanol to quench the endogenous peroxidase activity. Antigen retrieval was performed by incubation for 10 min at 121degreesC in citrate buffer (0.01 M, pH 6.0); sections were washed with phosphate-buffered saline (PBS), and incubated for 30 min in 10% normal goat serum (Harlan Sera-Lab, Loughborough, Leicestershire, UK). We incubated the sections with the primary antibodies overnight at 4degreesC. Hereafter, sections were washed in PBS and we used the ready-for-use Powervision peroxidase system (Immunologic, Duiven, The Netherlands) and 3,3'-diaminobenzidine as chromogen to develop the staining. Sections were counterstained with hematoxylin, dehydrated, and coverslipped. Sections incubated without the primary antibody and excess of the antigenic peptide were essentially blank.
###end p 25
###begin p 26
###xml 152 155 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 202 205 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 176 182 <span type="species:ncbi:9986">rabbit</span>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
###xml 365 371 <span type="species:ncbi:9986">rabbit</span>
For double-labeling studies, after incubation overnight at 4degreesC with the primary antibodies, sections were incubated for 2 h at RT with Alexa Fluor(R) 568-conjugated anti-rabbit IgG and Alexa Fluor(R) 488 anti-mouse IgG (1:1,000; Molecular Probes, The Netherlands). The VEGFR-2 antibody (monoclonal mouse) could only be combined with MAP2 and GFAP (polyclonal rabbit). Sections were analyzed by means of a laser scanning confocal microscope (Bio-Rad, Hercules, CA, USA; MRC1024) equipped with an argon-ion laser.
###end p 26
###begin title 27
Evaluation of immunostaining
###end title 27
###begin title 28
Semi-quantitative evaluation of immunoreactivity
###end title 28
###begin p 29
###xml 24 25 24 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 27 29 27 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 224 225 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 353 354 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 771 772 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1010 1011 1008 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1013 1015 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 1019 1026 1017 1024 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1026 1156 1024 1154 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in different cellular types in cases of FCD (% of cases with immunoreactive cells)</p>
###xml 1026 1156 1024 1154 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in different cellular types in cases of FCD (% of cases with immunoreactive cells)</p></caption>
###xml 1156 1156 1154 1154 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"/>
###xml 1182 1183 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1156 1188 1154 1186 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="9">Focal cortical dysplasia (<italic>n</italic>&#160;=&#160;9)</th>
###xml 1156 1188 1154 1186 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3"/><th align="left" colspan="9">Focal cortical dysplasia (<italic>n</italic>&#160;=&#160;9)</th></tr>
###xml 1188 1195 1186 1193 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Neurons</th>
###xml 1195 1205 1193 1203 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Astrocytes</th>
###xml 1205 1218 1203 1216 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Balloon cells</th>
###xml 1188 1218 1186 1216 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="3">Neurons</th><th align="left" colspan="3">Astrocytes</th><th align="left" colspan="3">Balloon cells</th></tr>
###xml 1218 1219 1216 1217 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</th>
###xml 1219 1220 1217 1218 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</th>
###xml 1220 1222 1218 1220 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</th>
###xml 1222 1223 1220 1221 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</th>
###xml 1223 1224 1221 1222 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</th>
###xml 1224 1226 1222 1224 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</th>
###xml 1226 1227 1224 1225 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</th>
###xml 1227 1228 1225 1226 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</th>
###xml 1228 1230 1226 1228 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</th>
###xml 1218 1230 1216 1228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th></tr>
###xml 1156 1230 1154 1228 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3"/><th align="left" colspan="9">Focal cortical dysplasia (<italic>n</italic>&#160;=&#160;9)</th></tr><tr><th align="left" colspan="3">Neurons</th><th align="left" colspan="3">Astrocytes</th><th align="left" colspan="3">Balloon cells</th></tr><tr><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th></tr></thead>
###xml 1230 1235 1228 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VEGFA</td>
###xml 1235 1236 1233 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1236 1239 1234 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22%</td>
###xml 1239 1242 1237 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78%</td>
###xml 1242 1243 1240 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1243 1246 1241 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11%</td>
###xml 1246 1249 1244 1247 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">89%</td>
###xml 1249 1250 1247 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1250 1253 1248 1251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11%</td>
###xml 1253 1256 1251 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">89%</td>
###xml 1230 1256 1228 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">VEGFA</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td></tr>
###xml 1256 1261 1254 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VEGFB</td>
###xml 1261 1262 1259 1260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1262 1265 1260 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33%</td>
###xml 1265 1268 1263 1266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67%</td>
###xml 1268 1271 1266 1269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78%</td>
###xml 1271 1274 1269 1272 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22%</td>
###xml 1274 1275 1272 1273 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1275 1278 1273 1276 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78%</td>
###xml 1278 1281 1276 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22%</td>
###xml 1281 1282 1279 1280 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1256 1282 1254 1280 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">VEGFB</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td></tr>
###xml 1282 1289 1280 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VEGFR-1</td>
###xml 1289 1290 1287 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1290 1293 1288 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">55%</td>
###xml 1293 1296 1291 1294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">45%</td>
###xml 1296 1297 1294 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1297 1300 1295 1298 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22%</td>
###xml 1300 1303 1298 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78%</td>
###xml 1303 1304 1301 1302 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1304 1307 1302 1305 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33%</td>
###xml 1307 1310 1305 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67%</td>
###xml 1282 1310 1280 1308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">VEGFR-1</td><td align="left">0</td><td align="left">55%</td><td align="left">45%</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td></tr>
###xml 1310 1317 1308 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VEGFR-2</td>
###xml 1317 1318 1315 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1318 1321 1316 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11%</td>
###xml 1321 1324 1319 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">89%</td>
###xml 1324 1327 1322 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">55%</td>
###xml 1327 1331 1325 1329 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">45% </td>
###xml 1331 1332 1329 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1332 1336 1330 1334 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22% </td>
###xml 1336 1339 1334 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">45%</td>
###xml 1339 1342 1337 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33%</td>
###xml 1310 1342 1308 1340 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">VEGFR-2</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">55%</td><td align="left">45% </td><td align="left">0</td><td align="left">22% </td><td align="left">45%</td><td align="left">33%</td></tr>
###xml 1230 1342 1228 1340 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">VEGFA</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td></tr><tr><td align="left">VEGFB</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td></tr><tr><td align="left">VEGFR-1</td><td align="left">0</td><td align="left">55%</td><td align="left">45%</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td></tr><tr><td align="left">VEGFR-2</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">55%</td><td align="left">45% </td><td align="left">0</td><td align="left">22% </td><td align="left">45%</td><td align="left">33%</td></tr></tbody>
###xml 1156 1342 1154 1340 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="9">Focal cortical dysplasia (<italic>n</italic>&#160;=&#160;9)</th></tr><tr><th align="left" colspan="3">Neurons</th><th align="left" colspan="3">Astrocytes</th><th align="left" colspan="3">Balloon cells</th></tr><tr><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th></tr></thead><tbody><tr><td align="left">VEGFA</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td></tr><tr><td align="left">VEGFB</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td></tr><tr><td align="left">VEGFR-1</td><td align="left">0</td><td align="left">55%</td><td align="left">45%</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td></tr><tr><td align="left">VEGFR-2</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">55%</td><td align="left">45% </td><td align="left">0</td><td align="left">22% </td><td align="left">45%</td><td align="left">33%</td></tr></tbody></table>
###xml 1342 1345 1340 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCD</italic>
###xml 1390 1391 1388 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</italic>
###xml 1405 1406 1403 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 1417 1419 1415 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">++</italic>
###xml 1342 1426 1340 1424 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><italic>FCD</italic> focal cortical dysplasia; immunoreactivity: <italic>&#8722;</italic> not present, <italic>+</italic> moderate, <italic>++</italic> strong</p>
###xml 1342 1426 1340 1424 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31"><italic>FCD</italic> focal cortical dysplasia; immunoreactivity: <italic>&#8722;</italic> not present, <italic>+</italic> moderate, <italic>++</italic> strong</p></table-wrap-foot>
###xml 1019 1426 1017 1424 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="30">VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in different cellular types in cases of FCD (% of cases with immunoreactive cells)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="9">Focal cortical dysplasia (<italic>n</italic>&#160;=&#160;9)</th></tr><tr><th align="left" colspan="3">Neurons</th><th align="left" colspan="3">Astrocytes</th><th align="left" colspan="3">Balloon cells</th></tr><tr><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th><th align="left">&#8722;</th><th align="left">+</th><th align="left">++</th></tr></thead><tbody><tr><td align="left">VEGFA</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td></tr><tr><td align="left">VEGFB</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td><td align="left">78%</td><td align="left">22%</td><td align="left">0</td></tr><tr><td align="left">VEGFR-1</td><td align="left">0</td><td align="left">55%</td><td align="left">45%</td><td align="left">0</td><td align="left">22%</td><td align="left">78%</td><td align="left">0</td><td align="left">33%</td><td align="left">67%</td></tr><tr><td align="left">VEGFR-2</td><td align="left">0</td><td align="left">11%</td><td align="left">89%</td><td align="left">55%</td><td align="left">45% </td><td align="left">0</td><td align="left">22% </td><td align="left">45%</td><td align="left">33%</td></tr></tbody></table><table-wrap-foot><p textid="31"><italic>FCD</italic> focal cortical dysplasia; immunoreactivity: <italic>&#8722;</italic> not present, <italic>+</italic> moderate, <italic>++</italic> strong</p></table-wrap-foot></table-wrap>
As previously reported [3, 54], a semi-quantitative analysis was done using an Olympus microscope and examining in each section, high-power non overlapping fields (of 0.0655 x 0.0655 mm width, each corresponding to 4.290 mum2), defined in the center of the lesion using a square grid inserted into the eyepiece. A total microscopical area of 858.050 mum2 was assessed per case. Neuronal cell bodies were differentiated from glia and glia-neuronal balloon cells on the basis of morphology. Balloon cells have eccentric nuclei and ballooned opalescent eosinophilic cytoplasm. The staining intensity was evaluated using a semi-quantitative three-point scale where immunoreactivity was defined as: - absent (0); + moderate (1); ++ strong staining (2); intensity score (Table 2). This score represents the predominant cell staining intensity found in each section for the different cell types (neurons, astrocytes, microglial cells, and balloon cells) as averaged from the selected fields (as previously described [3, 54]). Table 2VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in different cellular types in cases of FCD (% of cases with immunoreactive cells)Focal cortical dysplasia (n = 9)NeuronsAstrocytesBalloon cells-+++-+++-+++VEGFA022%78%011%89%011%89%VEGFB033%67%78%22%078%22%0VEGFR-1055%45%022%78%033%67%VEGFR-2011%89%55%45% 022% 45%33%FCD focal cortical dysplasia; immunoreactivity: - not present, + moderate, ++ strong
###end p 29
###begin p 30
VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in different cellular types in cases of FCD (% of cases with immunoreactive cells)
###end p 30
###begin p 31
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCD</italic>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</italic>
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 75 77 75 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">++</italic>
FCD focal cortical dysplasia; immunoreactivity: - not present, + moderate, ++ strong
###end p 31
###begin title 32
Frequency of cell staining
###end title 32
###begin p 33
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
In each slice, we assessed the number of neurons and astrocytes labeled by a specific Ab on the total number of each cell type within the lesion using an ocular grid [4]. This frequency score was assigned using three distinct categories: (1) <10%, rare; (2) 11-30%, sparse; (3) >30%, high. The product of the intensity and the frequency scores was taken to give the total immunoreactivity score, as previously reported [23, 54].
###end p 33
###begin p 34
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
For statistical analysis of data, SPSS for Windows was used. Data were compared using a non-parametric Kruskal-Wallis test followed by a Mann-Whitney test to assess the difference between groups. P < 0.05 was taken as the level of significance.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human material and histological features
###end title 36
###begin p 37
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
All nine patients had chronic pharmacoresistant epilepsy and were all seizure-free postoperatively (Engel's class I; Table 1). The FCD cases included in this study have all the histopathological features of severe (type IIB) FCD, according to the classification of Palmini et al. [48]. The resected specimens consisted of disorganized neocortex containing immature neurons, giant neurons, dysmorphic neurons, and balloon cells. Neurons and balloon cells were also observed in the subcortical white matter and there was a prominent population of reactive astrocytes. Cells of the microglia/macrophage lineage were also observed within the dysplastic cortex, suggesting activation of inflammatory processes in FCD [6].
###end p 37
###begin title 38
Expression of VEGF and VEGFR in normal temporal cortex and FCD
###end title 38
###begin title 39
Cellular distribution of VEGFA
###end title 39
###begin p 40
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 418 424 418 424 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 485 486 485 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 562 563 562 563 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 630 635 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 657 658 657 658 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 757 758 757 758 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 818 824 818 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 827 828 827 828 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 877 878 877 878 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 930 931 930 931 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 968 969 968 969 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 971 972 971 972 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1014 1020 1014 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 1024 1025 1024 1025 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1069 1070 1069 1070 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1071 1072 1071 1072 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1098 1103 1098 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1105 1106 1105 1106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1120 1123 1120 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1125 1126 1125 1126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1151 1157 1151 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 1159 1160 1159 1160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1177 1178 1177 1178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 1179 1180 1179 1180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">o</bold>
###xml 1246 1251 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1253 1254 1253 1254 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 1268 1271 1268 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1273 1274 1273 1274 <bold xmlns:xlink="http://www.w3.org/1999/xlink">n</bold>
###xml 1299 1305 1299 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 1307 1308 1307 1308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">o</bold>
###xml 1333 1334 1333 1334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p</bold>
###xml 1381 1386 1381 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1400 1403 1400 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1421 1430 1421 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1434 1435 1434 1435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 424 1502 424 1497 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">VEGFA immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> VEGFA immunoreactivity (IR) within the histologically normal adult cortex. <bold>b</bold> High magnification showing somatic staining in pyramidal neurons (<italic>inset</italic>: vascular staining). <bold>c</bold> VEGFA in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>d</bold> High magnification showing VEGFA IR in dysplastic neurons (<italic>arrows</italic>). <bold>e</bold> A binucleated VEGFA positive dysplastic neuron. <bold>f</bold> VEGFA IR within the subcortical dysplastic region. <bold>g</bold> VEGFA expression in a balloon cell. <bold>h</bold>, <bold>i</bold> VEGFA expression in reactive astrocytes (<italic>arrows</italic> in <bold>i</bold> indicate perivascular astrocytic end-feet) <bold>j</bold>&#8211;<bold>l</bold> double-labeling of GFAP (<italic>green</italic>, <bold>j</bold>) with VEGFA (<italic>red</italic>, <bold>k</bold>) shows co-localization (<italic>yellow</italic>, <bold>l</bold>) in astrocytes. <bold>m</bold>&#8211;<bold>o</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>m</bold>) with VEGFA (<italic>red</italic>, <bold>n</bold>) shows co-localization (<italic>yellow</italic>, <bold>o</bold>) in dysplastic neurons. <bold>p</bold> Merged image showing co-localization of CD68 (<italic>green</italic>) with VEGFA (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, c, f 400&#160;&#956;m; b, d 120&#160;&#956;m; e, g&#8211;i 35&#160;&#956;m; j&#8211;o 40&#160;&#956;m; p 18&#160;&#956;m</p>
###xml 424 1502 424 1497 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">VEGFA immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> VEGFA immunoreactivity (IR) within the histologically normal adult cortex. <bold>b</bold> High magnification showing somatic staining in pyramidal neurons (<italic>inset</italic>: vascular staining). <bold>c</bold> VEGFA in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>d</bold> High magnification showing VEGFA IR in dysplastic neurons (<italic>arrows</italic>). <bold>e</bold> A binucleated VEGFA positive dysplastic neuron. <bold>f</bold> VEGFA IR within the subcortical dysplastic region. <bold>g</bold> VEGFA expression in a balloon cell. <bold>h</bold>, <bold>i</bold> VEGFA expression in reactive astrocytes (<italic>arrows</italic> in <bold>i</bold> indicate perivascular astrocytic end-feet) <bold>j</bold>&#8211;<bold>l</bold> double-labeling of GFAP (<italic>green</italic>, <bold>j</bold>) with VEGFA (<italic>red</italic>, <bold>k</bold>) shows co-localization (<italic>yellow</italic>, <bold>l</bold>) in astrocytes. <bold>m</bold>&#8211;<bold>o</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>m</bold>) with VEGFA (<italic>red</italic>, <bold>n</bold>) shows co-localization (<italic>yellow</italic>, <bold>o</bold>) in dysplastic neurons. <bold>p</bold> Merged image showing co-localization of CD68 (<italic>green</italic>) with VEGFA (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, c, f 400&#160;&#956;m; b, d 120&#160;&#956;m; e, g&#8211;i 35&#160;&#956;m; j&#8211;o 40&#160;&#956;m; p 18&#160;&#956;m</p></caption>
###xml 1502 1502 1497 1497 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig2_HTML" id="MO2"/>
###xml 418 1502 418 1497 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="41">VEGFA immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> VEGFA immunoreactivity (IR) within the histologically normal adult cortex. <bold>b</bold> High magnification showing somatic staining in pyramidal neurons (<italic>inset</italic>: vascular staining). <bold>c</bold> VEGFA in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>d</bold> High magnification showing VEGFA IR in dysplastic neurons (<italic>arrows</italic>). <bold>e</bold> A binucleated VEGFA positive dysplastic neuron. <bold>f</bold> VEGFA IR within the subcortical dysplastic region. <bold>g</bold> VEGFA expression in a balloon cell. <bold>h</bold>, <bold>i</bold> VEGFA expression in reactive astrocytes (<italic>arrows</italic> in <bold>i</bold> indicate perivascular astrocytic end-feet) <bold>j</bold>&#8211;<bold>l</bold> double-labeling of GFAP (<italic>green</italic>, <bold>j</bold>) with VEGFA (<italic>red</italic>, <bold>k</bold>) shows co-localization (<italic>yellow</italic>, <bold>l</bold>) in astrocytes. <bold>m</bold>&#8211;<bold>o</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>m</bold>) with VEGFA (<italic>red</italic>, <bold>n</bold>) shows co-localization (<italic>yellow</italic>, <bold>o</bold>) in dysplastic neurons. <bold>p</bold> Merged image showing co-localization of CD68 (<italic>green</italic>) with VEGFA (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, c, f 400&#160;&#956;m; b, d 120&#160;&#956;m; e, g&#8211;i 35&#160;&#956;m; j&#8211;o 40&#160;&#956;m; p 18&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig2_HTML" id="MO2"/></fig>
VEGFA staining was observed within the histologically normal cortex (Fig. 2a, b). The staining was strongest in pyramidal neurons, which displayed somatic staining and staining of the apical dendrites (Fig. 2b). Neuropil staining was weak and resting glial cells did not show VEGFA immunoreactivity (IR). Weak staining was observed in endothelial cells. Autopsy material and the perilesional cortex showed similar IR. Fig. 2VEGFA immunoreactivity in focal cortical dysplasia type IIB. a VEGFA immunoreactivity (IR) within the histologically normal adult cortex. b High magnification showing somatic staining in pyramidal neurons (inset: vascular staining). c VEGFA in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. d High magnification showing VEGFA IR in dysplastic neurons (arrows). e A binucleated VEGFA positive dysplastic neuron. f VEGFA IR within the subcortical dysplastic region. g VEGFA expression in a balloon cell. h, i VEGFA expression in reactive astrocytes (arrows in i indicate perivascular astrocytic end-feet) j-l double-labeling of GFAP (green, j) with VEGFA (red, k) shows co-localization (yellow, l) in astrocytes. m-o Double-labeling of non-phosphorylated neurofilament (SMI311; NF, green, m) with VEGFA (red, n) shows co-localization (yellow, o) in dysplastic neurons. p Merged image showing co-localization of CD68 (green) with VEGFA (red) in macrophages. Scale bar in a a, c, f 400 mum; b, d 120 mum; e, g-i 35 mum; j-o 40 mum; p 18 mum
###end p 40
###begin p 41
###xml 61 62 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 138 139 138 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 233 234 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 333 334 333 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 403 404 403 404 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 453 454 453 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 506 507 506 507 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 544 545 544 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 547 548 547 548 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 590 596 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 600 601 600 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 645 646 645 646 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 647 648 647 648 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 681 682 681 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 696 699 696 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 701 702 701 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 735 736 735 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 753 754 753 754 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 755 756 755 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink">o</bold>
###xml 822 827 822 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 829 830 829 830 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 844 847 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 849 850 849 850 <bold xmlns:xlink="http://www.w3.org/1999/xlink">n</bold>
###xml 875 881 875 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 883 884 883 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink">o</bold>
###xml 909 910 909 910 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p</bold>
###xml 957 962 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 976 979 976 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 997 1006 997 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1010 1011 1010 1011 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
VEGFA immunoreactivity in focal cortical dysplasia type IIB. a VEGFA immunoreactivity (IR) within the histologically normal adult cortex. b High magnification showing somatic staining in pyramidal neurons (inset: vascular staining). c VEGFA in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. d High magnification showing VEGFA IR in dysplastic neurons (arrows). e A binucleated VEGFA positive dysplastic neuron. f VEGFA IR within the subcortical dysplastic region. g VEGFA expression in a balloon cell. h, i VEGFA expression in reactive astrocytes (arrows in i indicate perivascular astrocytic end-feet) j-l double-labeling of GFAP (green, j) with VEGFA (red, k) shows co-localization (yellow, l) in astrocytes. m-o Double-labeling of non-phosphorylated neurofilament (SMI311; NF, green, m) with VEGFA (red, n) shows co-localization (yellow, o) in dysplastic neurons. p Merged image showing co-localization of CD68 (green) with VEGFA (red) in macrophages. Scale bar in a a, c, f 400 mum; b, d 120 mum; e, g-i 35 mum; j-o 40 mum; p 18 mum
###end p 41
###begin p 42
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
In the majority of FCD cases, strong VEGFA immunoreactivity (IR) was observed in dysplastic neurons located throughout the dysplastic cortex (Fig. 2c-e; Table 2; Fig. 6). Strong staining was also detected in balloon cells, reactive astrocytes, and in perivascular astrocytic end-feet (Fig. 2f-i; Table 2; Fig. 6). Endothelial IR was weak. Double-labeling experiments confirmed expression in reactive astrocytes, neurons, and in CD68+ macrophages (Fig. 2p). Immunocytochemistry using two different antibodies to VEGF (Pharmingen and Santa Cruz Bio.) demonstrated similar patterns.
###end p 42
###begin title 43
Cellular distribution of VEGFB
###end title 43
###begin p 44
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 209 215 209 215 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 276 277 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 469 477 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset aI</italic>
###xml 530 539 530 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset aII</italic>
###xml 542 543 542 543 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 642 643 642 643 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 711 717 711 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 720 721 720 721 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 762 768 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 771 772 771 772 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 773 774 773 774 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 816 821 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 823 824 823 824 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 838 841 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 843 844 843 844 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 861 862 861 862 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 879 880 879 880 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 881 882 881 882 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 948 953 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 955 956 955 956 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 970 973 970 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 975 976 975 976 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1001 1007 1001 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 1009 1010 1009 1010 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1035 1036 1035 1036 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1089 1094 1089 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1108 1111 1108 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1129 1138 1129 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1142 1143 1142 1143 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 215 1178 215 1175 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">VEGFB immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> Histologically normal adult cortex, showing neuronal distribution of VEGFB with weak immunoreactivity (IR) in pyramidal cell neurons (high magnification of a pyramidal neuron is shown in the <italic>inset aI</italic>); weak staining was also observed in blood vessels (<italic>inset aII</italic>). <bold>b</bold> VEGFB in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>c</bold> Strong VEGFB IR in dysplastic neurons of different size and shape (<italic>arrows</italic>). <bold>d</bold> Undetectable VEGFB IR in balloon cells (<italic>arrows</italic>). <bold>e</bold>&#8211;<bold>g</bold> Absence of co-localization between GFAP (<italic>green</italic>, <bold>e</bold>) with VEGFB (<italic>red</italic>, <bold>f</bold>) in astrocytes (<bold>g</bold>, merged image). <bold>h</bold>&#8211;<bold>j</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>h</bold>) with VEGFB (<italic>red</italic>, <bold>i</bold>) shows co-localization (<italic>yellow</italic>, <bold>j</bold>) in dysplastic neurons. <bold>k</bold> Merged image showing co-localization of CD68 (CD68; <italic>green</italic>) with VEGFB (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, b 200&#160;&#956;m; c&#8211;j 40&#160;&#956;m; k 18&#160;&#956;m</p>
###xml 215 1178 215 1175 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">VEGFB immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> Histologically normal adult cortex, showing neuronal distribution of VEGFB with weak immunoreactivity (IR) in pyramidal cell neurons (high magnification of a pyramidal neuron is shown in the <italic>inset aI</italic>); weak staining was also observed in blood vessels (<italic>inset aII</italic>). <bold>b</bold> VEGFB in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>c</bold> Strong VEGFB IR in dysplastic neurons of different size and shape (<italic>arrows</italic>). <bold>d</bold> Undetectable VEGFB IR in balloon cells (<italic>arrows</italic>). <bold>e</bold>&#8211;<bold>g</bold> Absence of co-localization between GFAP (<italic>green</italic>, <bold>e</bold>) with VEGFB (<italic>red</italic>, <bold>f</bold>) in astrocytes (<bold>g</bold>, merged image). <bold>h</bold>&#8211;<bold>j</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>h</bold>) with VEGFB (<italic>red</italic>, <bold>i</bold>) shows co-localization (<italic>yellow</italic>, <bold>j</bold>) in dysplastic neurons. <bold>k</bold> Merged image showing co-localization of CD68 (CD68; <italic>green</italic>) with VEGFB (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, b 200&#160;&#956;m; c&#8211;j 40&#160;&#956;m; k 18&#160;&#956;m</p></caption>
###xml 1178 1178 1175 1175 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig3_HTML" id="MO3"/>
###xml 209 1178 209 1175 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="45">VEGFB immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold> Histologically normal adult cortex, showing neuronal distribution of VEGFB with weak immunoreactivity (IR) in pyramidal cell neurons (high magnification of a pyramidal neuron is shown in the <italic>inset aI</italic>); weak staining was also observed in blood vessels (<italic>inset aII</italic>). <bold>b</bold> VEGFB in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. <bold>c</bold> Strong VEGFB IR in dysplastic neurons of different size and shape (<italic>arrows</italic>). <bold>d</bold> Undetectable VEGFB IR in balloon cells (<italic>arrows</italic>). <bold>e</bold>&#8211;<bold>g</bold> Absence of co-localization between GFAP (<italic>green</italic>, <bold>e</bold>) with VEGFB (<italic>red</italic>, <bold>f</bold>) in astrocytes (<bold>g</bold>, merged image). <bold>h</bold>&#8211;<bold>j</bold> Double-labeling of non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>, <bold>h</bold>) with VEGFB (<italic>red</italic>, <bold>i</bold>) shows co-localization (<italic>yellow</italic>, <bold>j</bold>) in dysplastic neurons. <bold>k</bold> Merged image showing co-localization of CD68 (CD68; <italic>green</italic>) with VEGFB (<italic>red</italic>) in macrophages. <italic>Scale bar</italic> in <bold>a</bold> a, b 200&#160;&#956;m; c&#8211;j 40&#160;&#956;m; k 18&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig3_HTML" id="MO3"/></fig>
Histologically normal cortex displayed only weak VEGFB IR (Fig. 3a). Both autopsy and surgical specimens showed light staining in pyramidal neurons and in endothelial cells. Glial cells did not show VEGFB IR. Fig. 3VEGFB immunoreactivity in focal cortical dysplasia type IIB. a Histologically normal adult cortex, showing neuronal distribution of VEGFB with weak immunoreactivity (IR) in pyramidal cell neurons (high magnification of a pyramidal neuron is shown in the inset aI); weak staining was also observed in blood vessels (inset aII). b VEGFB in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. c Strong VEGFB IR in dysplastic neurons of different size and shape (arrows). d Undetectable VEGFB IR in balloon cells (arrows). e-g Absence of co-localization between GFAP (green, e) with VEGFB (red, f) in astrocytes (g, merged image). h-j Double-labeling of non-phosphorylated neurofilament (SMI311; NF, green, h) with VEGFB (red, i) shows co-localization (yellow, j) in dysplastic neurons. k Merged image showing co-localization of CD68 (CD68; green) with VEGFB (red) in macrophages. Scale bar in a a, b 200 mum; c-j 40 mum; k 18 mum
###end p 44
###begin p 45
###xml 61 62 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 254 262 254 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset aI</italic>
###xml 315 324 315 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset aII</italic>
###xml 327 328 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 427 428 427 428 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 505 506 505 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 556 557 556 557 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 558 559 558 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 608 609 608 609 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 623 626 623 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 628 629 628 629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 646 647 646 647 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 664 665 664 665 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 666 667 666 667 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 733 738 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 740 741 740 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 755 758 755 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 760 761 760 761 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 794 795 794 795 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 820 821 820 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 874 879 874 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 893 896 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 914 923 914 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 927 928 927 928 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
VEGFB immunoreactivity in focal cortical dysplasia type IIB. a Histologically normal adult cortex, showing neuronal distribution of VEGFB with weak immunoreactivity (IR) in pyramidal cell neurons (high magnification of a pyramidal neuron is shown in the inset aI); weak staining was also observed in blood vessels (inset aII). b VEGFB in focal cortical dysplasia (FCD; type IIB) showing strong IR within the dysplastic cortex. c Strong VEGFB IR in dysplastic neurons of different size and shape (arrows). d Undetectable VEGFB IR in balloon cells (arrows). e-g Absence of co-localization between GFAP (green, e) with VEGFB (red, f) in astrocytes (g, merged image). h-j Double-labeling of non-phosphorylated neurofilament (SMI311; NF, green, h) with VEGFB (red, i) shows co-localization (yellow, j) in dysplastic neurons. k Merged image showing co-localization of CD68 (CD68; green) with VEGFB (red) in macrophages. Scale bar in a a, b 200 mum; c-j 40 mum; k 18 mum
###end p 45
###begin p 46
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
In FCD specimens, moderate to strong VEGFB IR was observed within the dysplastic cortex (Fig. 3b; Table 2; Fig. 6) with strong VEGFB IR in dysplastic neurons (Fig. 3c). In the majority of cases (seven out of nine), balloon cells and reactive astrocytes did not express VEGFB (Fig. 3d; Table 2; Fig. 6). Double-labeling experiments confirmed the absence of VEGFB IR in GFAP-positive cells (astrocytes), whereas co-localization was found with neurofilament in dysplastic neurons (Fig. 3h-j). VEGFB IR was also observed in CD68+ macrophages (Fig. 3k).
###end p 46
###begin title 47
Cellular distribution of VEGFR-1
###end title 47
###begin p 48
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 224 230 224 230 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 293 294 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 296 297 296 297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 334 335 334 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 355 356 355 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 405 406 405 406 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 427 428 427 428 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 430 440 430 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 443 444 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 446 447 446 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 541 542 541 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 574 575 574 575 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 595 596 595 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 667 672 667 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 688 691 688 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 716 721 716 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 725 726 725 726 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 777 782 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 798 801 798 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 821 822 821 822 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 823 824 823 824 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 871 877 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 896 906 896 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 910 911 910 911 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 914 915 914 915 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 916 917 916 917 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 948 953 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 955 956 955 956 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 972 975 972 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 977 978 977 978 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 995 996 995 996 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1013 1014 1013 1014 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1015 1016 1015 1016 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 1048 1053 1048 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1055 1056 1055 1056 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1072 1075 1072 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1077 1078 1077 1078 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1096 1097 1096 1097 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 1114 1123 1114 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1127 1128 1127 1128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 230 1159 230 1157 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">VEGFR-1 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing weak immunoreactivity (IR) in neurons (<bold>a</bold>) and blood vessels (<bold>b</bold>; <italic>arrowheads</italic>). <bold>c</bold>, <bold>d</bold> VEGFR-1 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<bold>c</bold>; <italic>arrows</italic>) and in blood vessels (<bold>d</bold>; <italic>arrows</italic>). <italic>Inset</italic> in <bold>c</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in dysplastic neurons. <italic>Inset</italic> in <bold>d</bold> Co-localization between CD31 (endothelial marker; <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in blood vessels. <bold>e</bold>&#8211;<bold>g</bold> Strong IR in balloon cells of different size (<italic>arrows</italic>) and glial cells (<italic>arrowheads</italic> in <bold>e</bold>). <bold>h</bold>&#8211;<bold>j</bold> Co-localization between GFAP (<italic>green</italic>, <bold>h</bold>) with VEGFR-1 (<italic>red</italic>, <bold>i</bold>) in astrocytes (<bold>j</bold>, merged image). <bold>k</bold>&#8211;<bold>m</bold> Co-localization of CD68 (CD68; <italic>green</italic>, <bold>k</bold>) with VEGFR-1 (<italic>red</italic>, <bold>l</bold>) in macrophages (<bold>m</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and h&#8211;m 40&#160;&#956;m; e&#8211;g 35&#160;&#956;m</p>
###xml 230 1159 230 1157 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">VEGFR-1 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing weak immunoreactivity (IR) in neurons (<bold>a</bold>) and blood vessels (<bold>b</bold>; <italic>arrowheads</italic>). <bold>c</bold>, <bold>d</bold> VEGFR-1 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<bold>c</bold>; <italic>arrows</italic>) and in blood vessels (<bold>d</bold>; <italic>arrows</italic>). <italic>Inset</italic> in <bold>c</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in dysplastic neurons. <italic>Inset</italic> in <bold>d</bold> Co-localization between CD31 (endothelial marker; <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in blood vessels. <bold>e</bold>&#8211;<bold>g</bold> Strong IR in balloon cells of different size (<italic>arrows</italic>) and glial cells (<italic>arrowheads</italic> in <bold>e</bold>). <bold>h</bold>&#8211;<bold>j</bold> Co-localization between GFAP (<italic>green</italic>, <bold>h</bold>) with VEGFR-1 (<italic>red</italic>, <bold>i</bold>) in astrocytes (<bold>j</bold>, merged image). <bold>k</bold>&#8211;<bold>m</bold> Co-localization of CD68 (CD68; <italic>green</italic>, <bold>k</bold>) with VEGFR-1 (<italic>red</italic>, <bold>l</bold>) in macrophages (<bold>m</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and h&#8211;m 40&#160;&#956;m; e&#8211;g 35&#160;&#956;m</p></caption>
###xml 1159 1159 1157 1157 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig4_HTML" id="MO4"/>
###xml 224 1159 224 1157 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="49">VEGFR-1 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing weak immunoreactivity (IR) in neurons (<bold>a</bold>) and blood vessels (<bold>b</bold>; <italic>arrowheads</italic>). <bold>c</bold>, <bold>d</bold> VEGFR-1 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<bold>c</bold>; <italic>arrows</italic>) and in blood vessels (<bold>d</bold>; <italic>arrows</italic>). <italic>Inset</italic> in <bold>c</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in dysplastic neurons. <italic>Inset</italic> in <bold>d</bold> Co-localization between CD31 (endothelial marker; <italic>green</italic>) with VEGFR-1 (<italic>red</italic>) in blood vessels. <bold>e</bold>&#8211;<bold>g</bold> Strong IR in balloon cells of different size (<italic>arrows</italic>) and glial cells (<italic>arrowheads</italic> in <bold>e</bold>). <bold>h</bold>&#8211;<bold>j</bold> Co-localization between GFAP (<italic>green</italic>, <bold>h</bold>) with VEGFR-1 (<italic>red</italic>, <bold>i</bold>) in astrocytes (<bold>j</bold>, merged image). <bold>k</bold>&#8211;<bold>m</bold> Co-localization of CD68 (CD68; <italic>green</italic>, <bold>k</bold>) with VEGFR-1 (<italic>red</italic>, <bold>l</bold>) in macrophages (<bold>m</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and h&#8211;m 40&#160;&#956;m; e&#8211;g 35&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig4_HTML" id="MO4"/></fig>
Histologically normal cortex (autopsy and surgical specimens) displayed only weak VEGFR-1 IR, which was restricted to pyramidal neurons (Fig. 4a). IR in blood vessels was weak (Fig. 4b). Glial cells did not show VEGFR-1 IR. Fig. 4VEGFR-1 immunoreactivity in focal cortical dysplasia type IIB. a, b Histologically normal adult cortex (a) and white matter (b) showing weak immunoreactivity (IR) in neurons (a) and blood vessels (b; arrowheads). c, d VEGFR-1 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (c; arrows) and in blood vessels (d; arrows). Inset in c Co-localization between non-phosphorylated neurofilament (SMI311; NF, green) with VEGFR-1 (red) in dysplastic neurons. Inset in d Co-localization between CD31 (endothelial marker; green) with VEGFR-1 (red) in blood vessels. e-g Strong IR in balloon cells of different size (arrows) and glial cells (arrowheads in e). h-j Co-localization between GFAP (green, h) with VEGFR-1 (red, i) in astrocytes (j, merged image). k-m Co-localization of CD68 (CD68; green, k) with VEGFR-1 (red, l) in macrophages (m, merged image). Scale bar in a a-d and h-m 40 mum; e-g 35 mum
###end p 48
###begin p 49
###xml 63 64 63 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 66 67 66 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 175 176 175 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 197 198 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 200 210 200 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 213 214 213 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 216 217 216 217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 311 312 311 312 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 344 345 344 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 365 366 365 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 495 496 495 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 591 592 591 592 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 593 594 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 666 676 666 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 680 681 680 681 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 684 685 684 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 686 687 686 687 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 725 726 725 726 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 742 745 742 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 747 748 747 748 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 765 766 765 766 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 783 784 783 784 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 785 786 785 786 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 825 826 825 826 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 842 845 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 847 848 847 848 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 866 867 866 867 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
###xml 884 893 884 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 897 898 897 898 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
VEGFR-1 immunoreactivity in focal cortical dysplasia type IIB. a, b Histologically normal adult cortex (a) and white matter (b) showing weak immunoreactivity (IR) in neurons (a) and blood vessels (b; arrowheads). c, d VEGFR-1 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (c; arrows) and in blood vessels (d; arrows). Inset in c Co-localization between non-phosphorylated neurofilament (SMI311; NF, green) with VEGFR-1 (red) in dysplastic neurons. Inset in d Co-localization between CD31 (endothelial marker; green) with VEGFR-1 (red) in blood vessels. e-g Strong IR in balloon cells of different size (arrows) and glial cells (arrowheads in e). h-j Co-localization between GFAP (green, h) with VEGFR-1 (red, i) in astrocytes (j, merged image). k-m Co-localization of CD68 (CD68; green, k) with VEGFR-1 (red, l) in macrophages (m, merged image). Scale bar in a a-d and h-m 40 mum; e-g 35 mum
###end p 49
###begin p 50
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
In FCD specimens, moderate to strong VEGFR-1 staining was observed within the dysplastic cortex (Fig. 4c-g; Table 2; Fig. 6). VEGFR-1 IR was observed in different cell types, including dysplastic neurons, astrocytes, and endothelial cells. Double-labeling experiments confirmed the co-localization of VEGFR-1 IR with neuronal (inset in Fig. 4c), endothelial (inset in Fig. 4d), and glial (Fig. 4h-j) markers. Additionally, expression of VEGFR-1 was observed in CD68+ macrophages (Fig. 4k-m).
###end p 50
###begin title 51
Cellular distribution of VEGFR-2
###end title 51
###begin p 52
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 209 215 209 215 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 278 279 278 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 281 282 281 282 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 319 320 319 320 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 340 341 340 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 402 403 402 403 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 491 492 491 492 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 495 496 495 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 498 499 498 499 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 593 599 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 603 604 603 604 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 637 647 637 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 651 652 651 652 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 655 656 655 656 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 658 659 658 659 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 703 704 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 738 739 738 739 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 770 780 770 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 784 785 784 785 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 787 788 787 788 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 791 796 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 800 801 800 801 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 872 877 872 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 893 896 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 922 923 922 923 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 924 925 924 925 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 957 962 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 964 965 964 965 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 981 984 981 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 986 987 986 987 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1007 1008 1007 1008 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1025 1034 1025 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1038 1039 1038 1039 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 215 1071 215 1069 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53">VEGFR-2 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing moderate immunoreactivity (IR) in pyramidal cells (<bold>a</bold>); in the white matter, endothelial IR was weak and glial IR was under detection level (<bold>b</bold>). <bold>c</bold>, <bold>d</bold> VEGFR-2 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<italic>arrows</italic> in <bold>c</bold>), but weak IR in blood vessels (<italic>arrowheads</italic> in <bold>d</bold>). <bold>e</bold>, <bold>f</bold> Strong IR in a dysplastic neuron (<italic>arrow</italic> in <bold>e</bold>) and in a balloon cell (<italic>arrow</italic> in <bold>f</bold>), but weak IR in glial cells (<italic>arrowheads</italic> in <bold>e</bold>, <bold>f</bold>). <italic>Inset</italic> in <bold>e</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-2 (<italic>red</italic>) in a dysplastic neuron. <bold>g</bold>&#8211;<bold>i</bold> Co-localization between MAP-2 (<italic>green</italic>, <bold>g</bold>) with VEGFR-2 (<italic>red</italic>, <bold>h</bold>) in balloon cells (<bold>i</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and g&#8211;i 40&#160;&#956;m; e, f 35&#160;&#956;m</p>
###xml 215 1071 215 1069 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53">VEGFR-2 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing moderate immunoreactivity (IR) in pyramidal cells (<bold>a</bold>); in the white matter, endothelial IR was weak and glial IR was under detection level (<bold>b</bold>). <bold>c</bold>, <bold>d</bold> VEGFR-2 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<italic>arrows</italic> in <bold>c</bold>), but weak IR in blood vessels (<italic>arrowheads</italic> in <bold>d</bold>). <bold>e</bold>, <bold>f</bold> Strong IR in a dysplastic neuron (<italic>arrow</italic> in <bold>e</bold>) and in a balloon cell (<italic>arrow</italic> in <bold>f</bold>), but weak IR in glial cells (<italic>arrowheads</italic> in <bold>e</bold>, <bold>f</bold>). <italic>Inset</italic> in <bold>e</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-2 (<italic>red</italic>) in a dysplastic neuron. <bold>g</bold>&#8211;<bold>i</bold> Co-localization between MAP-2 (<italic>green</italic>, <bold>g</bold>) with VEGFR-2 (<italic>red</italic>, <bold>h</bold>) in balloon cells (<bold>i</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and g&#8211;i 40&#160;&#956;m; e, f 35&#160;&#956;m</p></caption>
###xml 1071 1071 1069 1069 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig5_HTML" id="MO5"/>
###xml 209 1071 209 1069 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="53">VEGFR-2 immunoreactivity in focal cortical dysplasia type IIB. <bold>a</bold>, <bold>b</bold> Histologically normal adult cortex (<bold>a</bold>) and white matter (<bold>b</bold>) showing moderate immunoreactivity (IR) in pyramidal cells (<bold>a</bold>); in the white matter, endothelial IR was weak and glial IR was under detection level (<bold>b</bold>). <bold>c</bold>, <bold>d</bold> VEGFR-2 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (<italic>arrows</italic> in <bold>c</bold>), but weak IR in blood vessels (<italic>arrowheads</italic> in <bold>d</bold>). <bold>e</bold>, <bold>f</bold> Strong IR in a dysplastic neuron (<italic>arrow</italic> in <bold>e</bold>) and in a balloon cell (<italic>arrow</italic> in <bold>f</bold>), but weak IR in glial cells (<italic>arrowheads</italic> in <bold>e</bold>, <bold>f</bold>). <italic>Inset</italic> in <bold>e</bold> Co-localization between non-phosphorylated neurofilament (SMI311; NF, <italic>green</italic>) with VEGFR-2 (<italic>red</italic>) in a dysplastic neuron. <bold>g</bold>&#8211;<bold>i</bold> Co-localization between MAP-2 (<italic>green</italic>, <bold>g</bold>) with VEGFR-2 (<italic>red</italic>, <bold>h</bold>) in balloon cells (<bold>i</bold>, merged image). <italic>Scale bar</italic> in <bold>a</bold> a&#8211;d and g&#8211;i 40&#160;&#956;m; e, f 35&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig5_HTML" id="MO5"/></fig>
VEGFR-2 staining was observed within the histologically normal cortex (autopsy and perilesional zone) in pyramidal neurons (Fig. 5a). IR in blood vessels was weak (Fig. 5b). Glial cells did not show VEGFB IR. Fig. 5VEGFR-2 immunoreactivity in focal cortical dysplasia type IIB. a, b Histologically normal adult cortex (a) and white matter (b) showing moderate immunoreactivity (IR) in pyramidal cells (a); in the white matter, endothelial IR was weak and glial IR was under detection level (b). c, d VEGFR-2 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (arrows in c), but weak IR in blood vessels (arrowheads in d). e, f Strong IR in a dysplastic neuron (arrow in e) and in a balloon cell (arrow in f), but weak IR in glial cells (arrowheads in e, f). Inset in e Co-localization between non-phosphorylated neurofilament (SMI311; NF, green) with VEGFR-2 (red) in a dysplastic neuron. g-i Co-localization between MAP-2 (green, g) with VEGFR-2 (red, h) in balloon cells (i, merged image). Scale bar in a a-d and g-i 40 mum; e, f 35 mum
###end p 52
###begin p 53
###xml 63 64 63 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 66 67 66 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 187 188 187 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 276 277 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 280 281 280 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 283 284 283 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 388 389 388 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 422 432 422 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 436 437 436 437 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 440 441 440 441 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 443 444 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 488 489 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 514 519 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 523 524 523 524 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 555 565 555 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 569 570 569 570 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 572 573 572 573 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 585 586 585 586 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 678 681 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 707 708 707 708 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 709 710 709 710 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 742 747 742 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 749 750 749 750 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 766 769 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 771 772 771 772 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 792 793 792 793 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 810 819 810 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 823 824 823 824 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
VEGFR-2 immunoreactivity in focal cortical dysplasia type IIB. a, b Histologically normal adult cortex (a) and white matter (b) showing moderate immunoreactivity (IR) in pyramidal cells (a); in the white matter, endothelial IR was weak and glial IR was under detection level (b). c, d VEGFR-2 in focal cortical dysplasia (FCD; type IIB) showing strong IR in dysplastic neurons (arrows in c), but weak IR in blood vessels (arrowheads in d). e, f Strong IR in a dysplastic neuron (arrow in e) and in a balloon cell (arrow in f), but weak IR in glial cells (arrowheads in e, f). Inset in e Co-localization between non-phosphorylated neurofilament (SMI311; NF, green) with VEGFR-2 (red) in a dysplastic neuron. g-i Co-localization between MAP-2 (green, g) with VEGFR-2 (red, h) in balloon cells (i, merged image). Scale bar in a a-d and g-i 40 mum; e, f 35 mum
###end p 53
###begin p 54
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 584 590 584 590 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 660 681 660 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and methods</xref>
###xml 763 764 763 764 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 766 767 766 767 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 775 776 775 776 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 778 779 778 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 787 788 787 788 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 790 791 790 791 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 801 802 801 802 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 804 805 804 805 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 815 816 815 816 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 817 818 817 818 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 828 829 828 829 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 830 831 830 831 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1108 1109 1108 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 590 1229 590 1229 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">Distribution of immunoreactivity scores (total score; see details in &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#8221; section) in neurons and astrocytes of control, perilesional, and FCD specimens. <bold>a</bold>, <bold>e</bold> VEGFA; <bold>b</bold>, <bold>f</bold> VEGFB; <bold>c</bold>, <bold>g</bold> VEGFR-1; <bold>d</bold>, <bold>h</bold> VEGFR-2. <bold>a</bold>&#8211;<bold>d</bold> Neurons; <bold>e</bold>&#8211;<bold>h</bold> astrocytes. IR scores of VEGFs and VEGFRs in neurons of FCD were greater than IR scores of VEGFs and VEGFRs of control and perilesional cortex; scores of VEGFA and VEGFRs in astrocytes of FCD were greater than IR scores of VEGFA and VEGFRs of control and perilesional cortex (<italic>P</italic>&#160;&lt;&#160;0.05). There were no significant differences in IR scores of VEGFs and VEGFRs between control and perilesional cortex</p>
###xml 590 1229 590 1229 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55">Distribution of immunoreactivity scores (total score; see details in &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#8221; section) in neurons and astrocytes of control, perilesional, and FCD specimens. <bold>a</bold>, <bold>e</bold> VEGFA; <bold>b</bold>, <bold>f</bold> VEGFB; <bold>c</bold>, <bold>g</bold> VEGFR-1; <bold>d</bold>, <bold>h</bold> VEGFR-2. <bold>a</bold>&#8211;<bold>d</bold> Neurons; <bold>e</bold>&#8211;<bold>h</bold> astrocytes. IR scores of VEGFs and VEGFRs in neurons of FCD were greater than IR scores of VEGFs and VEGFRs of control and perilesional cortex; scores of VEGFA and VEGFRs in astrocytes of FCD were greater than IR scores of VEGFA and VEGFRs of control and perilesional cortex (<italic>P</italic>&#160;&lt;&#160;0.05). There were no significant differences in IR scores of VEGFs and VEGFRs between control and perilesional cortex</p></caption>
###xml 1229 1229 1229 1229 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_354_Fig6_HTML" id="MO6"/>
###xml 584 1229 584 1229 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="55">Distribution of immunoreactivity scores (total score; see details in &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#8221; section) in neurons and astrocytes of control, perilesional, and FCD specimens. <bold>a</bold>, <bold>e</bold> VEGFA; <bold>b</bold>, <bold>f</bold> VEGFB; <bold>c</bold>, <bold>g</bold> VEGFR-1; <bold>d</bold>, <bold>h</bold> VEGFR-2. <bold>a</bold>&#8211;<bold>d</bold> Neurons; <bold>e</bold>&#8211;<bold>h</bold> astrocytes. IR scores of VEGFs and VEGFRs in neurons of FCD were greater than IR scores of VEGFs and VEGFRs of control and perilesional cortex; scores of VEGFA and VEGFRs in astrocytes of FCD were greater than IR scores of VEGFA and VEGFRs of control and perilesional cortex (<italic>P</italic>&#160;&lt;&#160;0.05). There were no significant differences in IR scores of VEGFs and VEGFRs between control and perilesional cortex</p></caption><graphic position="anchor" xlink:href="401_2008_354_Fig6_HTML" id="MO6"/></fig>
In the large majority of FCD cases (eight out of nine), VEGFR-2 was strongly expressed in dysplastic neurons (Fig. 5c, e; Table 2; Fig. 6). VEGFR-2 IR was also detected in balloon cells, but only three out of nine cases displayed strong staining for VEGFR-2 (Fig. 5f; Table 2). Endothelial expression was weak. In many FCD cases (five out of nine), expression of VEGFR-2 was undetectable in reactive astrocytes (Table 2). Double-labeling experiments confirmed the co-localization of VEGFR-2 IR with neuronal markers (neurofilament or MAP2, Fig. 5e, g-i) within the dysplastic cortex. Fig. 6Distribution of immunoreactivity scores (total score; see details in "Materials and methods" section) in neurons and astrocytes of control, perilesional, and FCD specimens. a, e VEGFA; b, f VEGFB; c, g VEGFR-1; d, h VEGFR-2. a-d Neurons; e-h astrocytes. IR scores of VEGFs and VEGFRs in neurons of FCD were greater than IR scores of VEGFs and VEGFRs of control and perilesional cortex; scores of VEGFA and VEGFRs in astrocytes of FCD were greater than IR scores of VEGFA and VEGFRs of control and perilesional cortex (P < 0.05). There were no significant differences in IR scores of VEGFs and VEGFRs between control and perilesional cortex
###end p 54
###begin p 55
###xml 70 91 70 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and methods</xref>
###xml 173 174 173 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 176 177 176 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 185 186 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 188 189 188 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 197 198 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 200 201 200 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 211 212 211 212 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 214 215 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 225 226 225 226 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 227 228 227 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 238 239 238 239 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 240 241 240 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Distribution of immunoreactivity scores (total score; see details in "Materials and methods" section) in neurons and astrocytes of control, perilesional, and FCD specimens. a, e VEGFA; b, f VEGFB; c, g VEGFR-1; d, h VEGFR-2. a-d Neurons; e-h astrocytes. IR scores of VEGFs and VEGFRs in neurons of FCD were greater than IR scores of VEGFs and VEGFRs of control and perilesional cortex; scores of VEGFA and VEGFRs in astrocytes of FCD were greater than IR scores of VEGFA and VEGFRs of control and perilesional cortex (P < 0.05). There were no significant differences in IR scores of VEGFs and VEGFRs between control and perilesional cortex
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">69</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR76">76</xref>
In addition to their role in angiogenesis, VEGF proteins and their receptors have been implicated in several neurological disorders, including epilepsy [13, 44, 56]. In the present study, we demonstrate a prominent expression of VEGFA, VEGFB, and their signaling receptors in FCD type IIB, a malformation of cortical development associated with intractable epilepsy. This is particularly interesting in view of the recently proposed role of VEGFs and their signaling pathways during development and in epilepsy-associated pathologies [13, 26, 33, 69, 76].
###end p 57
###begin title 58
Expression of VEGFA and VEGFB in normal temporal cortex
###end title 58
###begin p 59
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR72">72</xref>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">78</xref>
###xml 289 294 <span type="species:ncbi:9606">human</span>
In histologically normal temporal cortex (autopsy and perilesional zone), we have shown weak expression of both VEGFA and VEGFB in cortical neurons. Expression of VEGFA and VEGFB, including both mRNA and protein, has been demonstrated in neurons in adult rodent brain [39, 41, 42, 72]. In human adult brain, only few studies have described neuronal expression of VEGFA in control tissue [8, 78], which was similar to our observed staining pattern in the control temporal specimens.
###end p 59
###begin p 60
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">78</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 279 282 <span type="species:ncbi:10116">rat</span>
To our knowledge, previous studies of VEGFB protein expression in human control cortex have not been described. However, VEGFB mRNA was detected in human hippocampal cortex [24], and VEGFB mRNA and protein expression has been described in adult rodent brain [36, 42]. In control rat brain, VEGFB was constitutively expressed in endothelial cells [42]. In our study, we observed only weak endothelial VEGFB IR in blood vessels. In agreement with previous studies [8, 36, 78], immunoreactivity (IR) for both VEGFs was not observed in glial cells within control specimens.
###end p 60
###begin title 61
Differential cellular distribution of VEGFA and VEGFB in FCD
###end title 61
###begin p 62
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">59</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">78</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR79">79</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
In the present study, we provide evidence for a consistent expression of both VEGFA and VEGFB within the dysplastic cortex of patients with FCD. Both VEGFs are highly expressed in dysplastic neurons; however, only the VEGFA protein is prominently expressed in reactive astrocytes. Expression of VEGFA in astrocytes has been shown in several other pathologies associated with reactive gliosis, such as ischemic stroke, traumatic brain injury, neurodegenerative disorders, and the hippocampus following entorhinal deafferentation [8, 27, 59, 78, 79]. In addition, we previously reported upregulation of both neuronal and glial VEGFA expression in patients with hemimegalenchephaly, an epilepsy-associated malformation of cortical development [5, 7]. In the present study, we also observed expression of VEGFA in balloon cells, which are characteristic cell types of severe FCD [48]. Whether these cells are glial or neuronal in nature is still controversial [12].
###end p 62
###begin p 63
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Induction of both neuronal and astroglial VEGFA expression has been shown in different experimental models of seizures and human temporal lobe epilepsy (TLE) [13, 44, 56]. Rigau et al. [56] showed increased levels of VEGFA in the hippocampus of several cases of TLE, including two cases of focal dysplasia. All TLE cases showed VEGFA expression in pyramidal neurons and granule cells of the hippocampus [56]. However, immunocytochemical analysis of the temporal cortex and the FCD cases was not performed.
###end p 63
###begin p 64
###xml 430 432 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 434 436 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 438 440 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">61</xref>
###xml 702 704 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 894 896 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1011 1020 985 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIF1&#945;</italic>
###xml 1025 1030 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGFA</italic>
###xml 1076 1077 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1265 1266 1235 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1268 1270 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1272 1274 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 1276 1278 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR77">77</xref>
###xml 1372 1374 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1376 1378 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1613 1615 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR76">76</xref>
###xml 1617 1619 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR77">77</xref>
###xml 1756 1758 1726 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR71">71</xref>
###xml 1915 1917 1885 1887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1919 1921 1889 1891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 1923 1925 1893 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
###xml 1058 1063 <span type="species:ncbi:9606">human</span>
###xml 1211 1216 <span type="species:ncbi:9606">human</span>
The molecular mechanism underlying the induction of VEGFA expression after seizures remains unclear. One possible mechanism, which has been proposed to explain the association between seizure activity and the induction of VEGFA expression, is represented by the stabilization of the hypoxia inducible factor-1alpha (HIF-1alpha). HIF-1alpha is a transcription factor which upregulates VEGFA transcription under hypoxic conditions [21, 38, 61]. Hypoxia may occur during seizures, representing an important trigger in the induction of VEGFA expression, particularly in case of long lasting seizures, such as in status epilepticus models. However, VEGFA expression is already induced after acute seizures [44] and the mechanisms that regulate VEGFA expression are complex. Several transcription factors, including AP-1, HIF-1alpha, and NF-kappaB, have been identified to regulate VEGFA expression [31], and recently it has also been shown that inflammatory cytokines, such as interleukin-1beta (IL-1beta), activate HIF1alpha and VEGFA gene expression in primary human astrocytes [2]. Interestingly, increased expression of proinflammatory cytokines and related molecules has been reported in both animal models and human epilepsy-associated pathologies, including FCD [3, 15, 54, 77]. In addition, VEGFA has been demonstrated to be a key mediator of the inflammatory process [14, 35]. Thus, we might speculate that the prominent expression of VEGFA within the dysplastic cortex could be a critical component of the complex cascade of events leading to a chronic inflammatory state and the sustained seizure activity [76, 77]. With respect to inflammation, inflammatory cells, such as macrophages, can also release various angiogenic cytokines including VEGFs [71]. Accordingly, we observed expression of both VEGFA and VEGFB in macrophages (CD68-positive cells), as previously shown in animal models of brain ischemia [11, 42, 52].
###end p 64
###begin p 65
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">60</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">55</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR75">75</xref>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 355 359 <span type="species:ncbi:10116">rats</span>
VEGFA effects can also compromise the integrity of the blood-brain barrier (BBB; [60]). Interestingly, alterations of the BBB permeability have been recently observed in both human and experimental temporal lobe epilepsy with positive correlation between the increased vascular permeability and the occurrence of spontaneous seizures in chronic epileptic rats [55, 56, 75].
###end p 65
###begin p 66
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">67</xref>
In contrast, several studies highlight a dichotomous function of VEGFA, also demonstrating a neuroprotective role [13, 47]. Administration of VEGFA and neuronal expression of VEGFA have been shown to stimulate neurogenesis in vitro and in vivo [9, 28]. In addition, it has been suggested that the neuroprotective effects of VEGFA are mediated by the neuronal VEGFR-2 and the subsequent activation of the PI3K/Akt survival pathway [32, 67].
###end p 66
###begin p 67
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">62</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">68</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">69</xref>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
VEGFB expression is not induced by hypoxia or several transcription factors known to regulate VEGFA expression [18], as the promoter region of VEGFB lacks HIF-1 and AP-1 sites [43, 62]. The regulation of the expression of VEGFB remains unknown. Since all cases examined were associated with epilepsy, we cannot exclude that chronic seizure activity could also contribute to the VEGFB expression in FCD specimens. Alternatively, since VEGFB expression has been shown to be prominent during early brain development [36], the strong neuronal expression of VEGFB could represent an intrinsic and immature feature of the dysplastic neuronal cells that could contribute to their survival. Recent studies using VEGFB knock-out mice demonstrate a neurotrophic and neuroprotective activity of VEGFB, exerting a direct action on neurons, and promoting neurogenesis [68, 69].
###end p 67
###begin p 68
This is an observational study and we were, therefore, not able to investigate the spatio-temporal regulation of the VEGF system. Further research in animal models of cortical dysplasia is clearly needed to elucidate the role of VEGFs and their signaling pathways in the histogenesis or epileptogenesis of developmental disorders.
###end p 68
###begin title 69
Expression of VEGF receptors in normal temporal cortex
###end title 69
###begin p 70
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">78</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR79">79</xref>
###xml 268 273 <span type="species:ncbi:9606">human</span>
In histologically normal temporal cortex (autopsy and perilesional zone), VEGFR-1 and VEGFR-2 showed a similar pattern of expression, with weak to moderate immunostaining in pyramidal neurons. Neuronal expression of VEGFRs' mRNA and protein has been reported in adult human and rodent brain, with strong expression in the hippocampus [8, 11, 78, 79]. In agreement with these studies, we did not detect glial VEGFR expression in histologically normal cortex and only weak VEGFR expression was observed in endothelial cells.
###end p 70
###begin title 71
Differential cellular distribution of VEGFR-1 and VEGFR-2 in FCD
###end title 71
###begin p 72
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR66">66</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR79">79</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Consistent expression of both VEGFR-1 and VEGFR-2 was detected within the dysplastic cortex of patients with FCD. Both receptors were upregulated in dysplastic neurons. Increased expression of the VEGFRs and, in particular VEGFR-1, was observed in reactive astrocytes. Upregulation of VEGFRs in neurons and reactive astrocytes has been shown in several other pathological conditions including ischemia, neurodegenerative diseases, and trauma [8, 11, 37, 39, 66, 79]. Recently, increased expression of VEGFR-2 has been shown in several cases of TLE, including two cases of cortical dysplasia [56]. Immunocytochemical analysis demonstrated expression only in endothelial cells, whereas neuronal VEGFR-2 IR was not detected in either control hippocampus or TLE specimens [56]. Differences in the phenotypes of cells expressing VEGFRs have been observed in several other studies [8, 30, 52]. These discrepancies may be caused by differences in experimental methods, tissue processing, or the use of different antibodies that recognize different epitopes.
###end p 72
###begin p 73
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">57</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 531 534 <span type="species:ncbi:10116">rat</span>
###xml 615 619 <span type="species:ncbi:10116">rats</span>
###xml 687 691 <span type="species:ncbi:10116">rats</span>
Our results support the neuronal expression of VEGFR-2 recently reported in human brain [8]. The similar expression pattern of VEGFA and VEGFR-2, with prominent neuronal IR, suggests autocrine/paracrine effects on dysplastic neurons, supporting the hypothesis of a mechanism to protect abnormal neurons from cell death associated with seizures. Autocrine and/or paracrine effects of VEGFA are supported by the observation that administration of VEGFA has been shown to induce mRNA and protein expression of both receptors in adult rat brain [34, 57]. A protective mechanism of VEGFA has been suggested in epileptic rats, showing that VEGFA may reduce spontaneous discharges in epileptic rats [40]. Therefore, upregulation of VEGFA could represent an endogenous compensatory mechanism to reduce excitability and to prevent cell loss after severe seizures. Accordingly, infusion of VEGFA into the hippocampus has been shown to protect against neuronal cell loss after pilocarpine-induced status epilepticus [45].
###end p 73
###begin p 74
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
In the present study, we also provide evidence for the expression of VEGFR-1 in activated cells of the microglia/macrophage lineage, which have been shown to be present in FCD specimens [6]. This is in agreement with previous in vitro and in vivo studies [11, 20] showing VEGFR-1 expression in activated microglial cells. These observations suggest that the microglia/macrophage lineage is also a target for VEGF, which may affect chemotaxis and proliferation of these cells, contributing to the inflammatory state in the epileptic brain.
###end p 74
###begin p 75
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">67</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
There is substantial information about the function and the signaling through VEGFR-2; in contrast, signaling through VEGFR-1 remains poorly understood and has been a matter of discussion. A decoy role has been proposed for VEGFR-1, but more recently, functional signaling via VEGFR-1 has been reported (for reviews see [43, 67]). These observations may give rise to new therapeutic strategies focusing on VEGFR-1 specific ligands, such as VEGFB [43].
###end p 75
###begin p 76
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
Although a rapid induction of VEGF and its receptors has been shown in different experimental models of seizures [13, 44, 56], seizures alone cannot account for changes in neuronal and glial expression in FCD since perilesional tissue was exposed to seizures but did not show significant upregulation of VEGFs and/or VEGFRs. Therefore, the lesion per se or the concomitant presence of the lesion and the epileptic activity, are likely to play a role in modulating the VEGF system in these developmental disorders.
###end p 76
###begin title 77
Conclusions
###end title 77
###begin p 78
###xml 534 542 <span type="species:ncbi:9606">patients</span>
Our observed cellular distribution of VEGFA, VEGFB, and their signaling receptors indicate that different cellular components of FCD are involved in VEGF-signaling. In this context, future studies, using both in vivo and in vitro models, will be important to achieve a better understanding of the role of the VEGF-mediated pathways in the histogenesis and epileptogenesis of developmental lesions associated with intractable chronic epilepsy. Presently, signaling via VEGF receptors is not targeted by existing therapies in epileptic patients, but it can be potentially useful in view of its involvement in the regulation of neurogenesis, inflammation, and BBB integrity. However, an effective therapeutic intervention based on modulation of the VEGF system has to take into consideration the specific role of VEGFA and VEGFB and the multiple effects (protective and/or detrimental) reported for VEGFA.
###end p 78
###begin p 79
This work was supported by the National Epilepsy Fund (NEF 05-11; E. Aronica and K. Boer) and by EU-FP7-project (202167; E. Aronica).
###end p 79
###begin p 80
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature
###end article-title 82
###begin article-title 83
IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program
###end article-title 83
###begin article-title 84
###xml 42 47 <span type="species:ncbi:9606">human</span>
Complement activation in experimental and human temporal lobe epilepsy
###end article-title 84
###begin article-title 85
Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia
###end article-title 85
###begin article-title 86
Altered expression of neurotransmitter-receptor subunit and uptake site mRNAs in hemimegalencephaly
###end article-title 86
###begin article-title 87
Evidence of activated microglia in focal cortical dysplasia
###end article-title 87
###begin article-title 88
A neuropathological study of two autopsy cases of syndromic hemimegalencephaly
###end article-title 88
###begin article-title 89
Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis
###end article-title 89
###begin article-title 90
VEGF links hippocampal activity with neurogenesis, learning and memory
###end article-title 90
###begin article-title 91
Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders
###end article-title 91
###begin article-title 92
###xml 80 83 <span type="species:ncbi:10116">rat</span>
Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 in rat hippocampus after transient forebrain ischemia
###end article-title 92
###begin article-title 93
Neurodevelopmental disorders as a cause of seizures: neuropathologic, genetic, and mechanistic considerations
###end article-title 93
###begin article-title 94
Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword
###end article-title 94
###begin article-title 95
VEGF-mediated inflammation precedes angiogenesis in adult brain
###end article-title 95
###begin article-title 96
###xml 60 63 <span type="species:ncbi:10116">rat</span>
Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus
###end article-title 96
###begin article-title 97
Angiogenesis: update 2005
###end article-title 97
###begin article-title 98
Outcome with respect to epileptic seizures
###end article-title 98
###begin article-title 99
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
###end article-title 99
###begin article-title 100
The role of vascular endothelial growth factor in angiogenesis
###end article-title 100
###begin article-title 101
Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells
###end article-title 101
###begin article-title 102
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
###end article-title 102
###begin article-title 103
The role of vascular endothelial growth factor in neurogenesis in adult brain
###end article-title 103
###begin article-title 104
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis
###end article-title 104
###begin article-title 105
###xml 54 59 <span type="species:ncbi:9606">human</span>
Expression of vascular endothelial growth factor-b in human astrocytoma
###end article-title 105
###begin article-title 106
From angiogenesis to neuropathology
###end article-title 106
###begin article-title 107
VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation
###end article-title 107
###begin article-title 108
###xml 61 66 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke
###end article-title 108
###begin article-title 109
Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo
###end article-title 109
###begin article-title 110
Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia
###end article-title 110
###begin article-title 111
###xml 142 145 <span type="species:ncbi:10116">rat</span>
Induction of vascular endothelial growth factor receptors and phosphatidylinositol 3'-kinase/Akt signaling by global cerebral ischemia in the rat
###end article-title 111
###begin article-title 112
Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis
###end article-title 112
###begin article-title 113
The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia
###end article-title 113
###begin article-title 114
###xml 87 92 <span type="species:ncbi:9606">human</span>
Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells
###end article-title 114
###begin article-title 115
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain
###end article-title 115
###begin article-title 116
Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases
###end article-title 116
###begin article-title 117
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse
###end article-title 117
###begin article-title 118
###xml 173 176 <span type="species:ncbi:10116">rat</span>
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat
###end article-title 118
###begin article-title 119
Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer
###end article-title 119
###begin article-title 120
Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors
###end article-title 120
###begin article-title 121
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures
###end article-title 121
###begin article-title 122
###xml 88 91 <span type="species:ncbi:10116">rat</span>
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues
###end article-title 122
###begin article-title 123
Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury
###end article-title 123
###begin article-title 124
The biology of vascular endothelial growth factor-B (VEGF-B)
###end article-title 124
###begin article-title 125
Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors
###end article-title 125
###begin article-title 126
Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus
###end article-title 126
###begin article-title 127
Vascular endothelial growth factor B, a novel growth factor for endothelial cells
###end article-title 127
###begin article-title 128
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
###end article-title 128
###begin article-title 129
Terminology and classification of the cortical dysplasias
###end article-title 129
###begin article-title 130
###xml 39 44 <span type="species:ncbi:9606">human</span>
Endothelial growth factor receptors in human fetal heart
###end article-title 130
###begin article-title 131
Signaling via vascular endothelial growth factor receptors
###end article-title 131
###begin article-title 132
###xml 77 82 <span type="species:ncbi:9606">human</span>
Expression and distribution of vascular endothelial growth factor protein in human brain tumors
###end article-title 132
###begin article-title 133
Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct
###end article-title 133
###begin article-title 134
Different networks, common growth factors: shared growth factors and receptors of the vascular and nervous system
###end article-title 134
###begin article-title 135
The IL-1beta system in epilepsy-associated malformations of cortical development
###end article-title 135
###begin article-title 136
###xml 125 130 <span type="species:ncbi:9606">human</span>
Innate and adaptive immune mechanisms during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy
###end article-title 136
###begin article-title 137
Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy
###end article-title 137
###begin article-title 138
Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo
###end article-title 138
###begin article-title 139
Biology of vascular endothelial growth factors
###end article-title 139
###begin article-title 140
Expression of vascular endothelial growth factor by reactive astrocytes and associated neoangiogenesis
###end article-title 140
###begin article-title 141
Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain
###end article-title 141
###begin article-title 142
HIF-1: using two hands to flip the angiogenic switch
###end article-title 142
###begin article-title 143
###xml 39 44 <span type="species:ncbi:9606">human</span>
Analysis of the promoter region of the human VEGF-related factor gene
###end article-title 143
###begin article-title 144
Vascular endothelial growth factor-B promotes in vivo angiogenesis
###end article-title 144
###begin article-title 145
###xml 107 112 <span type="species:ncbi:9606">human</span>
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites
###end article-title 145
###begin article-title 146
Measurement of protein using bicinchoninic acid
###end article-title 146
###begin article-title 147
###xml 97 102 <span type="species:ncbi:9606">human</span>
Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis
###end article-title 147
###begin article-title 148
Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor
###end article-title 148
###begin article-title 149
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice
###end article-title 149
###begin article-title 150
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration
###end article-title 150
###begin article-title 151
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
###end article-title 151
###begin article-title 152
Macrophages and angiogenesis
###end article-title 152
###begin article-title 153
###xml 34 37 <span type="species:ncbi:10116">rat</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis
###end article-title 153
###begin article-title 154
Recent advances in the neuropathology of focal lesions in epilepsy
###end article-title 154
###begin article-title 155
Combined use of subdural and intracerebral electrodes in preoperative evaluation of epilepsy
###end article-title 155
###begin article-title 156
Long-lasting increased permeability of the blood-brain barrier may contribute to seizure progression in temporal lobe epilepsy
###end article-title 156
###begin article-title 157
VEGF and seizures: cross-talk between endothelial and neuronal environments
###end article-title 157
###begin article-title 158
Brain inflammation in epilepsy: experimental and clinical evidence
###end article-title 158
###begin article-title 159
Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease
###end article-title 159
###begin article-title 160
Vascular endothelial growth factor and its receptor Flk-1 are expressed in the hippocampus following entorhinal deafferentation
###end article-title 160
###begin article-title 161
Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia
###end article-title 161
###begin article-title 162
Molecular and functional diversity of vascular endothelial growth factors
###end article-title 162

